Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifamycin SV-MMX in acute uncomplicated diverticulitis (phase 2, double-blind, placebo-controlled)
2012-003300-13Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifamycin SV-MMX in acute diverticulitis (AD) and diverticulitis (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Treatment success at day 10 visit. Started Dec 2012; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
acute diverticulitis (AD)diverticulitis
Beyond the preview
Go deeper on 2012-003300-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003300-13.